Previous 10 | Next 10 |
BOSTON, MA / ACCESSWIRE / April 17, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the...
2023-03-29 15:41:29 ET The following slide deck was published by Pieris Pharmaceuticals, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Pieris Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation
2023-03-29 15:40:06 ET Pieris Pharmaceuticals, Inc. (PIRS) Q4 2022 Results Earnings Conference Call March 29, 2023, 08:00 AM ET Company Participants Thomas Bures - Senior Vice President and Chief Financial Officer Stephen Yoder - President and Chief Executive Officer...
2023-03-29 11:04:07 ET Pieris Pharmaceuticals ( NASDAQ: PIRS ) stock fell ~17% on Wednesday after the company's mixed FY22 results. Net loss narrowed to -$33.28M, compared to -$45.74M in 2021. Meanwhile, full year 2022 revenue declined -17.5% Y/Y to $25.9M. "Pi...
2023-03-29 10:05:07 ET Gainers: Kodiak Sciences ( KOD ) +19% . Arcturus Therapeutics ( ARCT ) +16% . Erasca ( ERAS ) +15% . G Medical Innovations ( GMVD ) +15% . Atai Life Sciences ( ATAI ) +13% . Losers: ProQR The...
2023-03-29 08:23:45 ET Draganfly DPRO -17% on proposed securities offering . SomaLogic SLGC -15% on Q4 earnings release . Shift Technologies SFT -15% on Q4 earnings release . Sharecare SHCR -12% on Q4 earnings release . Allarity Therapeu...
2023-03-29 07:05:41 ET Pieris Pharmaceuticals press release ( NASDAQ: PIRS ): FY GAAP EPS of -$0.45 beats by $0.02 . Revenue of $25.9M (-17.5% Y/Y) misses by $0.67M . Cash, cash equivalents, and investments totaled $59.2 million for the year ended December 31, ...
COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MARCH 29, 2023, AT 8:00 AM EDT Continued advancement of pipeline, including two clinical-stage inhaled respiratory programs and additional therapeutic programs for serious diseases Elarekibep (PRS-060/AZD1402) Phase 2a study...
2023-03-28 14:23:38 ET Pieris Pharmaceuticals ( NASDAQ: PIRS ) is scheduled to announce Q4 earnings results on Wednesday, March 29th, before market open. The consensus EPS Estimate is -$0.13 and the consensus Revenue Estimate is $6.51M For further details see: Pi...
BOSTON, MA / ACCESSWIRE / March 24, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) ,a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced tha...
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
2024-04-23 09:02:03 ET Pieris Pharmaceuticals Inc (PIRS) announced stock split at a ratio of 1-for-80 on 2024-04-23 ... Full story available on KlickAnalytics.com